Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest
Recruiting
Phase 2
Phase 3
Interventional Study
Out of Hospital Cardiac Arrest
Ventricular Fibrillation
Defibrillation
CPR
ACLS
Sudden Death
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 916 (estimated)
- Sponsor
- Gabriel Riva · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Some of the patients affected by Out-of-hospital cardiac arrest (OHCA) with ventricular fibrillation (VF)/ventricular tachycardia (VT) do not respond to initial defibrillation. The survival decreases with number of defibrillations required to terminate VF/VT. In 2022, one prospective cluster randomized trial showed increased survival among (OHCA) patients in refractory VF using Double Sequential D…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* OHCA patients with VT/VF at first rhythm analysis and at least one defibrillation performed in standard (A-L) position
Exclusion Criteria:
* Age \< 18 years
* Obvious pregnancy
* Known preexisting Do Not Attempt Resuscitation order
Contacts